Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCOS-102 and Durvalumab in Advanced Peritoneal Malignancies
NCT02963831Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Sep 2017
- Primary completion
- Jun 2022
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ONCOS-102 in epithelial ovarian cancer (EOC), metastatic colorectal cancer (mCRC), appendiceal cancer, sponsored by Ludwig Cancer Research. Started Sep 2017; status: completed.
02
Drugs
ONCOS-102
03
Conditions
epithelial ovarian cancer (EOC)metastatic colorectal cancer (mCRC)appendiceal cancer
Beyond the preview
Go deeper on NCT02963831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963831.